Tech Company Financing Transactions
Exsilio Therapeutics Funding Round
On 6/25/2024, Exsilio Therapeutics raised $82 million in Series A funding from Delos Capital, Novartis Venture Fund and Arc Capital.
Transaction Overview
Company Name
Announced On
6/25/2024
Transaction Type
Venture Equity
Amount
$82,000,000
Round
Series A
Investors
Delos Capital (Lead Investor)
Novartis Venture Fund (Lead Investor)
Proceeds Purpose
The company intends to use the funds to expand operations and its development efforts.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
Undisclosed
Boston, MA Undisclosed
USA
Boston, MA Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Overview
Exsilio is developing genomic medicines that insert therapeutic genes into safe harbors within the DNA. Backed by leading investors, we're on a mission to transform the treatment of a broad range of diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Tal Zaks
Browse more venture capital transactions:
Prev: 6/25/2024: Rocketlane venture capital transaction
Next: 6/25/2024: Zuub venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC investment data records reported here come from a variety of public sources. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs